Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 1, 2007, Pages 56-64

  Kim, Chan Duck ^a   Kwon, Hyeog Man ^a   Park, Sun Hee ^a   Oh, Eun Joo ^a   Kim, Mi Hyung ^a   Choi, Soon Youn ^a   Choi, Min Jeong ^a   Kim, In San ^a   Park, Min Sun ^c   Kim, Yong Jin ^b   Kim, Yong Lim ^a,d  

^a Kyungpook National University School of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Renal Asia   (South Korea)

^d Kyungpook National University Hospital   (South Korea)

Author keywords

Glucose degradation products; Peritoneal fibrosis; Transforming growth factor induced gene h3 ( ig h3); Transforming growth factor 1 (TGF 1); Vascularization

Indexed keywords

DIANEAL; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; LECTIN; LIPOPOLYSACCHARIDE; PERITONEAL DIALYSIS FLUID; PROTEIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA INDUCED GENE H3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UREA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BLOOD VESSEL; CONTROLLED STUDY; DIALYSATE; DIALYSIS CATHETER; FIBROGENESIS; FIBROSIS; GLUCOSE TRANSPORT; INFUSION; MALE; MEMBRANE; MESOTHELIUM; NONHUMAN; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEUM; PH; PLASMA; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; THICKNESS;

ANIMALS; BLOTTING, WESTERN; DIALYSIS SOLUTIONS; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; GLUCOSE; IMMUNOHISTOCHEMISTRY; MALE; PERITONEAL DIALYSIS; PERITONEUM; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33846988960     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00431.x     Document Type: Article

References (20)

1. Wieslander AP, Kjellstrand PT, Rippe B. Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alteration. Perit Dial Int 1995;15:S52-9.
2. Wieslander A, Forsback G, Svensson E, Linden T. Cytotoxicity, pH, and glucose degradation products in four different brands of PD fluids. Adv Perit Dial 1996;12:57-60.
3. Linden T, Forsback G, Deppisch R et al. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998;18:290-3.
4. Park SH, Lee EG, Kim IS et al. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Perit Dial Int 2004;24:115-22.
5. Wieczorowska-Tobis K, Brelinska R, Witowski J et al. Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 2004;24:48-57.
6. Musi B, Braide M, Carlsson O et al. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int 2004;24:37-47.
7. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004;66:1257-65.
8. Moore HL. A chronic catheter model for PD exchanges in the ambulatory rat (Abstract). Perit Dial Int 1992;12:141.
9. Waniewski J, Heimburger O, Werynski A, Lindholm B. Aqueous solute concentration and evaluation of mass transport coefficient in peritoneal dialysis. Nephrol Dial Transplant 1992;7:50-6.
10. Margetts PJ, Kolb M, Yu L et al. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int 2001;21:S368-72.
11. Lee SH, Bae JS, Park SH et al. Expression of TGF-β-induced matrix protein βig-h3 is up-regulated in the diabetic rat kidney and human proximal tubular epithelial cells treated with high glucose. Kidney Int 2003;64:1012-21.
12. Seo MJ, Oh SJ, Kim SI et al. High glucose dialysis solutions increase synthesis of vascular endothelial growth factors by peritoneal vascular endothelial cells. Perit Dial Int 2001;21:S35-40.
13. Kang DH, Hong YS, Lim HJ et al. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int 1999;19:221-30.
14. De Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001;12:1734-41.
15. Hekking LH, Zareie M, Driesprong BA et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001;12:2775-86.
16. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-57.
17. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-18.
18. Inagi R, Miyata T, Yamamoto T et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999;463:260-4.
19. Musi B, Carlsson O, Rippe A et al. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats. Perit Dial Int 1998;18:303-10.
20. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005;67:1559-65.